What to Expect
Prospective patients with autoimmune diseases should call study coordinators Gretchen Henstorf or Bernie McLauglin to make an appointment.
There is a fairly lengthy process before treatment can begin for autoimmune diseases. When you call, you will be told about the studies available to treat your disease and if you initially appear to be eligible. Your medical records will be sent to the study coordinators for review and eligibility determination; they will submit the apparent eligible patients to the study rheumatologist or neurologist. Patients are then brought to the rheumatology or neurology sites for a consenting conference and an initial Phase I screening to determine eligibility.
If approved by the study rheumatologist or neurologist, you will then be brought to the Seattle Cancer Care Alliance clinic for Phase II screening and testing.
If you are deemed eligible on screening, they will submit your information to the study Eligibility Review Committee for official approval. After that, you can be registered with SCCA and the coordinators will move forward with insurance approval and with scheduling your second screening testing.
Contact the study coordinators: